MyPath Melanoma
23-gene qRT-PCR expression classifier for ambiguous melanocytic lesions.
- Developer
- Castle Biosciences
- Intended use
- Diagnostic Aid
- Cancer scope
- Cutaneous melanoma
- Specimen
- FFPE tumor tissue
- Molecular modality
- RNA expression
- Current version
- MyPath Melanoma current 23-gene GEP (2026)
- Evidence context
- 1 structured studies · 2 indexed performance results · 3 sources
Why can reported performance numbers differ? MDI keeps each result attached to its study, population, stage or stratum, test version and source rather than treating performance as a fixed property of the test.